Vaccines against Emerging Infectious Diseases
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against Infectious Diseases".
Deadline for manuscript submissions: 30 June 2024 | Viewed by 3908
Special Issue Editors
Interests: vaccine development against emerging and re-emerging RNA viruses; the study of B cell and T cell responses to viral infection and vaccination
Special Issue Information
Dear Colleagues,
In recent decades, several emerging and re-emerging RNA virus-induced infectious viral diseases, such as Ebola hemorrhagic fever, Marburg hemorrhagic fever, Lassa fever, Nipah fever, Rift Valley Fever, dengue fever, yellow fever, West Nile fever, congenital Zika syndrome, as well as Chikungunya fever, swine flu, severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and the more recent COVID-19 complications, have threatened human and animal health and had significant impacts on public health and economies worldwide. Vaccination continues to be the most effective global strategy for the control and prevention of infectious diseases in humans and animals. Despite continuous efforts to develop effective vaccines, licensed vaccines are not yet available for the control of many of these emerging and re-emerging viruses. Therefore, there is an urgent need to develop safe and effective vaccines to prevent emerging infectious viral diseases.
This Special Issue is titled “Virus Vaccines and Emerging Infectious Diseases”. We would like to invite original research articles, as well as reviews, on topics related to vaccine development, including vaccine discovery, novel vaccine delivery platform, vaccine safety, vaccine formulation, novel vaccine adjuvant, immunogenicity and vaccinology studies, immunological responses to vaccine targets, immune correlates of vaccine-induced host protection, and preclinical and clinical studies of vaccines.
Dr. Awadalkareem Adam
Dr. Xuping Xie
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- emerging viruses
- vaccine development
- veterinary vaccine
- human vaccine
- emerging infectious diseases
